Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica.
Epstein-Barr virus: an important vaccine target for cancer prevention.
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
A phase II study of laquinimod in Crohn's disease.
Pharmaceutical approval update.
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Anejaculatory infertility due to multiple sclerosis.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
FDA warns about seizures linked to MS drug
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Confounding in association studies: month of birth and multiple sclerosis.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.

Pages